BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation
NYSE:BHC • CA0717341071
Current stock price
5.63 USD
+0.09 (+1.62%)
At close:
5.63 USD
0 (0%)
After Hours:
This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BHC Profitability Analysis
1.1 Basic Checks
- In the past year BHC was profitable.
- In the past year BHC had a positive cash flow from operations.
- In the past 5 years BHC reported 4 times negative net income.
- Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 0.60%, BHC belongs to the best of the industry, outperforming 80.10% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 7.78%, BHC belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
- BHC had an Average Return On Invested Capital over the past 3 years of 6.89%. This is significantly below the industry average of 13.11%.
- The 3 year average ROIC (6.89%) for BHC is below the current ROIC(7.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- With an excellent Profit Margin value of 1.53%, BHC belongs to the best of the industry, outperforming 80.10% of the companies in the same industry.
- BHC's Operating Margin of 21.28% is amongst the best of the industry. BHC outperforms 88.48% of its industry peers.
- In the last couple of years the Operating Margin of BHC has grown nicely.
- With a decent Gross Margin value of 70.65%, BHC is doing good in the industry, outperforming 77.49% of the companies in the same industry.
- In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. BHC Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BHC is creating some value.
- BHC has more shares outstanding than it did 1 year ago.
- BHC has more shares outstanding than it did 5 years ago.
- BHC has a better debt/assets ratio than last year.
2.2 Solvency
- BHC has an Altman-Z score of 0.29. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of BHC (0.29) is comparable to the rest of the industry.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- BHC's Debt to FCF ratio of 21.00 is fine compared to the rest of the industry. BHC outperforms 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.19
WACC6.54%
2.3 Liquidity
- BHC has a Current Ratio of 1.47. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of BHC (1.47) is worse than 76.44% of its industry peers.
- BHC has a Quick Ratio of 1.08. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of BHC (1.08) is worse than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. BHC Growth Analysis
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- BHC shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.13% yearly.
- BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
- BHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.04% yearly.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- BHC is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.34% yearly.
- Based on estimates for the next years, BHC will show a decrease in Revenue. The Revenue will decrease by -0.94% on average per year.
EPS Next Y21.76%
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. BHC Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 1.49, the valuation of BHC can be described as very cheap.
- BHC's Price/Earnings ratio is rather cheap when compared to the industry. BHC is cheaper than 100.00% of the companies in the same industry.
- BHC is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 1.23 indicates a rather cheap valuation of BHC.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
- BHC is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.24, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.49 | ||
| Fwd PE | 1.23 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BHC is valued cheaper than 95.29% of the companies in the same industry.
- BHC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.12 | ||
| EV/EBITDA | 6.37 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BHC may justify a higher PE ratio.
- BHC's earnings are expected to decrease with -5.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
5. BHC Dividend Analysis
5.1 Amount
- BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BHC Fundamentals: All Metrics, Ratios and Statistics
5.63
+0.09 (+1.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-29 2026-04-29
Inst Owners44.98%
Inst Owner Change0.02%
Ins Owners11.09%
Ins Owner Change10.2%
Market Cap2.10B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.39 (31.26%)
Short Float %1.85%
Short Ratio2.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)-0.47%
PT rev (3m)0.57%
EPS NQ rev (1m)-6.59%
EPS NQ rev (3m)-6.38%
EPS NY rev (1m)5.29%
EPS NY rev (3m)7.09%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)-1.02%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.49 | ||
| Fwd PE | 1.23 | ||
| P/S | 0.2 | ||
| P/FCF | 2.12 | ||
| P/OCF | 1.5 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.37 |
EPS(TTM)3.77
EY66.96%
EPS(NY)4.59
Fwd EY81.54%
FCF(TTM)2.66
FCFY47.23%
OCF(TTM)3.75
OCFY66.58%
SpS27.49
BVpS-1.48
TBVpS-44.1
PEG (NY)0.07
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.54%
ROIC/WACC1.19
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y21.76%
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year34.28%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.11%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
What is the valuation status of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
What is the profitability of BHC stock?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
How financially healthy is BAUSCH HEALTH COS INC?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.
What is the earnings growth outlook for BAUSCH HEALTH COS INC?
The Earnings per Share (EPS) of BAUSCH HEALTH COS INC (BHC) is expected to grow by 21.76% in the next year.